Growth Factor News and Research

RSS

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

Insight into breast cancer

Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond to particular therapies.

5 May 2011

BUSM research shows how heparan sulfate interacts with growth factor proteins

When the human genome project produced a map of human genes, the number of genes in humans turned out to be relatively small, approximately the same number as in primitive nematode worms.

5 May 2011

Animal studies reveal new route to treating heart disease

Scientists at Johns Hopkins have shown in laboratory experiments in mice that blocking the action of a signaling protein deep inside the heart’s muscle cells blunts the most serious ill effects of high blood pressure on the heart. These include heart muscle enlargement, scar tissue formation and loss of blood vessel growth.

2 May 2011

Brain-derived protein in colorectal cancer

Tumor progression is usually ensured by more than one proliferative mechanism. When one of these is shut down by a specifically targeted drug, other mechanisms may emerge. While these events may lead to treatment failure, they may also become an opportunity for researchers to identify novel targets to be further explored.

27 Apr 2011

Heparan sulfate may have a key role in tumor-spurred lymphatic vessel growth

Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.

27 Apr 2011

Worm protein controls key aspects of secretion of growth factors out of cells

Research in the worm is shedding light on a protein associated with a number of different human cancers, and may point to a highly targeted way to treat them.

22 Apr 2011

JASN publishes positive results from pirfenidone study in diabetic nephropathy

Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology.

22 Apr 2011

Researchers discover strategy that promotes new blood vessel formation

Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.

18 Apr 2011

Klotho hormone can protect kidney from renal fibrosis

A natural hormone known to inhibit aging can also protect kidneys against renal fibrosis, UT Southwestern Medical Center researchers have demonstrated.

15 Apr 2011

FDA panel votes in favour of Sunitib (Sutent) for pancreatic tumors

Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.

12 Apr 2011

Wrist circumference may predict insulin resistance and cardiovascular risk

Measuring the wrist bone may be a new way to identify which overweight children and adolescents face an increased risk of developing cardiovascular disease, according to research in Circulation: Journal of the American Heart Association.

12 Apr 2011

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that new preclinical data of their investigational compound custirsen in castrate resistant prostate cancer were presented this week at the 102nd Annual Meeting of the AACR.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

Having children early in life lowers lifetime risk of breast cancer

Women who have children, particularly early in life, have a lower lifetime risk of breast cancer compared with women who do not. Now, Fox Chase Cancer Center researchers have identified a gene expression pattern in breast tissue that differs between post-menopausal women who had children and post-menopausal women who did not.

6 Apr 2011

Under stressful conditions, presence of high levels of HER2 protein causes a decrease in autophagy

Research from The Cancer Institute of New Jersey (CINJ) on biological pathways that govern progression and treatment responsiveness of HER2 positive breast cancer is being presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held in Orlando this week. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Apr 2011

Neurotech’s NT-501 intraocular implant slows progression of vision loss in GA subjects

Neurotech Pharmaceuticals, Inc., today announced that it was reported in the Proceedings of the National Academy of Sciences that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in a Phase 2 study.

6 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011